Comparison of Single-Agent Androgen Suppression for Advanced Prostate Cancer

Reviews in Urology

Herbert Lepor¹ 

[1] Department of Urology, New York University School of Medicine, New York, NY

关键词: Androgen suppression;    Gonadotropin-releasing hormone agonists;    Orchiectomy;    Luteinizing hormone-releasing hormone;    Prostate cancer;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Gonadotropin-releasing hormone (GnRH) agonists are the agents of choice for achieving androgen suppression in men with advanced prostate cancer. The GnRH agonists that have been developed and marketed for prostate cancer are leuprolide, goserelin, triptorelin, and histrelin. So far, there have been few randomized studies directly comparing these single-agent therapies; however, the literature and the data on file with the Food and Drug Administration suggest that triptorelin may be more reliable than leuprolide in maintaining castration levels of serum testosterone. The clinical significance of this benefit remains to be proven.

【 授权许可】

Unknown